IMMU-132 for cervical cancer that returned or did not go away
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial studies IMMU-132 (sacituzumab govitecan) in people whose cervical cancer keeps coming back or stays after prior treatment. It aims to shrink tumors and improve outcomes after at least one chemotherapy has already been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer confirmed by a tissue test (biopsy), and it is persistent or recurrent on CT and/or MRI.
- You’ve had at least one prior chemotherapy treatment regimen, and your cancer progressed after it.
- You must have measurable tumors that can be tracked on scans, with at least one “target lesion” available for response measurement.
- You must have recent tumor tissue available (a FFPE pathology block) for TROP-2 testing.
- Your blood counts and organ function must be adequate (bone marrow, kidneys, and liver) and your body strength is limited to ECOG 0–1.
- You need to be at least 2 weeks past prior treatment and recovered from side effects to Grade 1 or better (with some exceptions for certain nerve issues and hair loss).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
This study tests a combination of two immunotherapy drugs and a targeted antibody-drug before standard treatment for locally advanced cervical cancer. The goal is to see if this triple therapy can shrink tumors more effectively before surgery or radiation.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) plus radiation for women whose cervical cancer has come back or spread to a few places in the body. The goal is to see if this treatment can shrink tumors and help patients live longer.
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
This study tests a drug called sacituzumab govitecan (a targeted therapy that delivers chemotherapy directly to cancer cells) for people with mesothelioma that has already been treated with other therapies. The goal is to see if the drug can shrink tumors and help control the disease.
This trial tests a combination of two drugs—sacituzumab govitecan and cetuximab—for people with advanced head and neck cancer that has gotten worse after immunotherapy. The goal is to see if this new treatment can shrink or slow the cancer.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.